Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, the Netherlands.
Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121 1066 CX, Amsterdam, the Netherlands.
Lung Cancer. 2017 Nov;113:102-105. doi: 10.1016/j.lungcan.2017.09.010. Epub 2017 Sep 18.
In summary, the PD-L1 biomarker discussed here highlights the importance of understanding the practice of IHC. This can be used to the patients advantage, with appropriate usage. The currently available literature on PD-L1 IHC from a methodologic point of view has not shown that different assays are comparable. The route of laboratory developed test and commercial test validation is the same: challenging and complex. Executing this process along proper methodologic lines is needed to ensure that patients receive the most accurate and representative test outcomes.
总之，这里讨论的 PD-L1 生物标志物强调了理解免疫组织化学实践的重要性。通过适当的使用，这可以使患者受益。从方法学的角度来看，目前关于 PD-L1 IHC 的可用文献并未表明不同的检测方法具有可比性。实验室开发的检测和商业检测的验证途径是相同的：具有挑战性和复杂性。需要沿着适当的方法学路线执行此过程，以确保患者获得最准确和最具代表性的检测结果。
